Tuesday, March 17, 2026

A Few Lost Brain Cells May Cause Dangerous Blood Pressure Instability

Scientists have discovered a group of brainstem cells that help keep blood pressure stable as the body moves through daily activities.

A normal average blood pressure reading may not tell the whole story. Scientists are finding that the size of the ups and downs between one moment and the next can matter just as much. When those short-term swings become too large, they are strongly linked to a higher risk of heart disease, stroke, and brain injury.

Now, researchers at the University of Virginia School of Medicine have identified a set of brain-stem nerve cells that appears to act like a built-in buffering system for blood pressure. The brain-stem helps run essential automatic functions, and this newly identified group of cells seems to keep blood pressure from changing too sharply as the body moves through ordinary transitions such as sleeping, waking, standing, and exercising. In simple terms, the study points to a brain circuit that may help the body smooth out constant pressure changes before they become harmful.

This is important because blood pressure is never truly fixed. It shifts from minute to minute as the body adjusts to posture, movement, stress, and rest. Doctors have traditionally focused on the average reading, but growing evidence suggests that stability itself may be a separate marker of health.

What we found is that a loss of just a few hundred nerve cells leads to unstable blood pressure even though the mean blood pressure was normal,” said UVA’s Stephen Abbott, PhD, the lead investigator of the study. “This shows that the system that keeps blood pressure steady from moment to moment is no longer working.”

Links to Neurological Disease

Scientists have already observed damage or dysfunction in these same brain cells in people with multiple system atrophy, a rare and fatal neurological disorder related to Parkinson’s disease that is known for causing severe problems with blood pressure control.

The new results suggest that similar brain mechanisms could also contribute to unstable blood pressure in other conditions, even when standard measurements show that a person’s average blood pressure appears normal. The researchers say this insight could eventually lead to treatments designed to reduce dangerous blood pressure fluctuations and limit the harm they can cause.

“Our work emphasizes a new appreciation for how we think about blood pressure problems,” Abbott said. “It’s not just about lowering the numbers – it’s about keeping blood pressure stable from moment to moment.” 

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

Labels: , ,

Sudden Sight Loss Risk Almost 5x Higher With Wegovy Than Ozempic, Study Finds

While GLP-1 drugs such as Wegovy and Ozempic are now being broadly championed and widely used, several studies are revealing some potentially worrying side effects – including new research that looks in detail at related vision loss.

These medications are so named because of how they mimic the effects of the glucagon-like peptide-1 (GLP-1) hormone to suppress appetite, aid digestion, and regulate blood sugar. They've been extensively prescribed to help with weight loss and manage diabetes.

However, reports of eyesight problems related to GLP-1 drugs and their active ingredient, semaglutide, are on the rise, prompting medicines regulators in the UK and Europe to review the risks based on available data.

In this new study, a team from universities across Canada analyzed records of adverse events collected by the US Food and Drug Administration (FDA) over 7 years, 2017-2024, and looked for cases of ischemic optic neuropathy (ION).

The rare condition can cause sudden and complete vision loss due to a lack of blood flow to the optic nerve – and it can be permanent in some cases.

The researchers wanted to see how many cases of ION occurred in people taking different semaglutide formulations: Wegovy (for weight loss), Ozempic (for type 2 diabetes), and Rybelsus (for type 2 diabetes).

"These findings extend our prior global analysis and, whereas previous studies identified only an agent-specific association, this study provides the first evidence of a formulation- and dose-dependent ION risk, with the strongest association observed for Wegovy," write the researchers in their published paper.

The statistical analysis deployed by the team found that the odds of a Wegovy-related ION complaint were almost five times higher than with Ozempic, while no clear relationship was found between Rybelsus and ION.

That's a stark difference, but it's important to put the numbers into context. The FDA database the researchers analyzed included more than 30 million so-called adverse events, and of these, there were a total of 28 cases linking Wegovy to ION and 47 cases linking Ozempic to ION.

While that Ozempic number is higher, it's been prescribed for a lot longer than Wegovy. Even so, the researchers found the strongest ION signal with Wegovy, and this persisted after adjusting for demographic factors such as age and sex: The odds of ION among Wegovy users were 4.74 times higher than with Ozempic, based on reported cases.

There was a clear difference between the sexes, too: Men taking semaglutide of any kind were about three times more likely to report a case of ION than women using GLP-1 drugs.

While these results are associations from one particular FDA database – not risk estimates for the general, global population prescribed semaglutide – they are still concerning to experts who say further research is necessary.

"These findings highlight a potential dose-dependent safety concern that warrants urgent prospective evaluation to guide prescribing and regulatory policy," the researchers write.

The team didn't examine why a link between GLP-1 drugs and vision loss might exist in this study, but they have a few ideas. It's possible that Wegovy, which has been approved for use at higher doses than other GLP-1 drugs, may lower blood pressure, perhaps reducing blood supply to the eye.

That's a hypothesis that further research can investigate. In the meantime, scientists are building a complex picture of GLP-1medications. Besides their primary effects, they have been linked with a host of other biological consequences, from reduced cancer risk to a greater likelihood of depression.

In a linked commentary, researchers from the University of Southampton in the UK (who were not involved in the study) discuss balancing the urgent need for anti-obesity strategies with the equally urgent need to make sure treatments are safe.

"Further studies providing nuanced information of this kind are therefore warranted," they conclude, "for better understanding of anti-obesity medication effects in the eye, especially given their increasing usage."

The research has been published in the British Journal of Ophthalmology.

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

 

Labels: ,

Friday, March 13, 2026

Some Thoughts About Growing Old Worth Smiling About

Growing old is not something we take seriously when we are children, teenagers, or when we first become adults. It is something we don't give importance to when we are young - but when we reach a certain age, we find it difficult to accept. The truth is, growing old teaches us a lot of things at every step of the way, even though it could bring about disappointment, dissatisfaction, and regrets. Just take life lightly, and live one step at a time - every age is precious! Here are a few thoughts worth reflecting on about our lives so far...

aging, wisdom, spirituality

 

aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality

  aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality aging, wisdom, spirituality 

 

aging, wisdom, spirituality

 aging, wisdom, spirituality 

 aging, wisdom, spirituality

  aging, wisdom, spirituality aging, wisdom, spirituality aging, wisdom, spirituality 

 aging, wisdom, spirituality aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality 

 aging, wisdom, spirituality

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

Labels: , , , ,